Oramed Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORMP research report →
Companywww.oramed.com
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
- CEO
- Nadav Kidron
- IPO
- 2007
- Employees
- 13
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $173.11M
- P/E
- 1.44
- P/S
- 0.00
- P/B
- 0.73
- EV/EBITDA
- 2.40
- Div Yield
- 5.84%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 60.96%
- ROIC
- -5.12%
Growth & Income
- Revenue
- $2.00M · 0.00%
- Net Income
- $64.05M · 494.30%
- EPS
- $1.53 · 425.53%
- Op Income
- $-15,088,000
- FCF YoY
- -8.59%
Performance & Tape
- 52W High
- $5.01
- 52W Low
- $1.98
- 50D MA
- $3.78
- 200D MA
- $2.99
- Beta
- 1.26
- Avg Volume
- 154.43K
Get TickerSpark's AI analysis on ORMP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | KIDRON NADAV | other | 44,818 |
| Mar 30, 26 | Kidron Miriam | other | 435,084 |
| Mar 17, 26 | Kidron Miriam | other | 119,558 |
| Mar 17, 26 | KIDRON NADAV | other | 167,005 |
| Mar 17, 26 | Hexter Joshua | other | 95,889 |
| Mar 17, 26 | Gabay Avraham | other | 95,889 |
| Mar 12, 26 | KIDRON NADAV | other | 100,000 |
| Jan 22, 26 | Hexter Joshua | other | 19,000 |
| Jan 22, 26 | Hexter Joshua | other | 19,000 |
| Jan 22, 26 | Kidron Miriam | other | 19,000 |
Our ORMP Coverage
We haven't published any research on ORMP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ORMP Report →